Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a report published on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners reiterated a “buy” rating on shares of Evogene in a research note on Friday, March 7th.

Evogene Trading Up 3.9 %

NASDAQ:EVGN opened at $1.05 on Friday. The firm has a market cap of $5.63 million, a price-to-earnings ratio of -0.23 and a beta of 1.37. Evogene has a 12-month low of $0.99 and a 12-month high of $9.00. The company’s 50-day moving average is $1.36 and its two-hundred day moving average is $1.71.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.78. The firm had revenue of $1.61 million for the quarter, compared to analyst estimates of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same quarter last year, the business earned ($1.30) earnings per share.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC purchased a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned approximately 0.30% of Evogene as of its most recent SEC filing. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.